Skip to main content
ConductScienceScienceDex

T John Winhusen

NIH Rank #9297
Unclaimed recordClaim profile
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 1908004Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Psychiatry

NIH Funding · FY2024

Linked Award Amount
$1.4M
Full award amounts, FY2024
Award Records
4
Records listing this PI
Award-Linked Rank
#9,297
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for T John Winhusen. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing T John Winhusen as a PI. Multi-PI records show the full award amount for context.

  • 3UG1DA013732-25S2UG1
    CTN - Effects of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro and Zepbound) on incidence and outcomes of stimulant use disorders and opioid use disorder in real-world populations: target tr
    University of Cincinnati
    $502.7K
    award amount
  • 3UG1DA013732-25S1UG1
    CTN - Evaluation of SeMaglutide as an Adjunct to buprenorphine treatment for the treatment of opioid use disorder: A pragmatic Randomized placebo-controlled Trial (SMART)
    University of Cincinnati
    $498.5K
    award amount
  • 5UG1DA013732-25UG1
    The Ohio Valley Node of the Clinical Trials Network
    University of Cincinnati
    $284.9K
    award amount
  • 3UG1DA013732-24S1UG1
    IMPROVE
    University of Cincinnati
    $146.3K
    award amount

Award organization

Organizations that administered FY2024 awards listing T John Winhusen as a PI.

FY2024 award administered by University of Cincinnati (OH).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    University of Cincinnati
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #9297
  5. 2025
    $2M Cumulative Funding
  6. 2025
    $5M Cumulative Funding
  7. 2025
    Entered Top 25% Nationally
    Ranked #573
  8. 2025
    Entered Top 10% Nationally
    Ranked #573
  9. 2025
    Entered Top 5% Nationally
    Ranked #573
  10. 2026
    $10M Cumulative Funding

Explore further

Find collaborators for T John Winhusen

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →